Plenty of ASX healthcare shares fell to 52-week lows today. The industry has not been immune to the ASX share market selloff.
There is ongoing volatility with investors keeping an eye on the Russian conflict with Ukraine, the sanctions and the ongoing inflation environment.
It has been a rough time for plenty of sectors, including healthcare:
Image source: Getty Images
Ramsay Health Care Limited (ASX: RHC)
The Ramsay Health Care share price fell to $59.85 earlier today. It's currently down by 0.5% to $60.30.
The business is a private hospital operator. The Ramsay Health Care share price has seen a drop of 16% since the start of the year.
Ramsay recently reported in the first half of FY22 that revenue grew by 1.2% but statutory net profit after tax (NPAT) was down by 29.7% to $158.9 million.
AVITA Medical Inc (ASX: AVH)
The AVITA share price fell to $2.37 earlier today. At the time of writing it is down just over 2%.
The medical technology business provides the RECELL system. The AVITA share price has seen a decline by around 30% since the start of 2022.
The ASX healthcare share recently reported a 37% increase in revenue to $14 million, whilst the net loss decreased 9% to $14.4 million.
Starpharma Holdings Limited (ASX: SPL)
The Starpharma share price fell to $0.80 earlier today. Currently, it is down 1.2%.
The pharmaceutical business is engaged in the research, development, and commercialisation of dendrimer products. The Starpharma share price has fallen by around 37% since the beginning of the calendar year.
Volpara Health Technologies Ltd (ASX: VHT)
The Volpara share price has hit a low of $0.66, representing a decline of almost 3%.
Volpara is an ASX healthcare share, which provides practice software as well as tools for breast screening and analysing those images. The Volpara share price has fallen by more than 36% since the start of the year.
The company has been reporting quarterly growth for a number of quarters.
It recently revealed that in the three months to 31 December 2021, cash receipts had grown by 50% year on year to NZ$7 million.
In that quarterly update, it said that annual recurring revenue (ARR) had now reached around US$21.5 million, or NZ$30.4 million in New Zealand dollar terms. This was up almost US$1.1 million over three months.
The ASX healthcare share's market share has now reached 35% of US women being screened, up from 34% in the prior quarter.
Volpara also said that the average revenue (ARPU) over the installed base of users was US$1.47 at the end of its third quarter, with average ARPU for deals in the third quarter of US$1.65, ranging from US$1.05 to US$6.68.
